aTyr Pharma, Inc. (ATYR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, aTyr Pharma, Inc. (ATYR) has a cash flow conversion efficiency ratio of -0.181x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.20 Million) by net assets ($67.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ATYR defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
aTyr Pharma, Inc. - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how aTyr Pharma, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
aTyr Pharma, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of aTyr Pharma, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Incross Co. Ltd
KQ:216050
|
0.049x |
|
Bonia Corporation Bhd
KLSE:9288
|
0.021x |
|
Kairous Acquisition Corp Ltd
NASDAQ:KACL
|
-0.008x |
|
Comtrend Corp
TWO:8089
|
0.105x |
|
GFG Resources Inc
V:GFG
|
-0.012x |
|
Mind Technology Inc
NASDAQ:MIND
|
0.022x |
|
Mudajaya Group Bhd
KLSE:5085
|
-0.012x |
|
Renishaw PLC
LSE:RSW
|
0.040x |
Annual Cash Flow Conversion Efficiency for aTyr Pharma, Inc. (2012–2025)
The table below shows the annual cash flow conversion efficiency of aTyr Pharma, Inc. from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see ATYR market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $67.29 Million | $-61.99 Million | -0.921x | +6.93% |
| 2024-12-31 | $69.83 Million | $-69.12 Million | -0.990x | -169.55% |
| 2023-12-31 | $90.47 Million | $-33.22 Million | -0.367x | +37.51% |
| 2022-12-31 | $71.28 Million | $-41.89 Million | -0.588x | -93.87% |
| 2021-12-31 | $109.13 Million | $-33.08 Million | -0.303x | +37.63% |
| 2020-12-31 | $31.48 Million | $-15.30 Million | -0.486x | +48.94% |
| 2019-12-31 | $21.03 Million | $-20.01 Million | -0.952x | -3.11% |
| 2018-12-31 | $33.65 Million | $-31.06 Million | -0.923x | -39.99% |
| 2017-12-31 | $64.25 Million | $-42.36 Million | -0.659x | +21.66% |
| 2016-12-31 | $62.80 Million | $-52.86 Million | -0.842x | -163.17% |
| 2015-12-31 | $115.05 Million | $-36.80 Million | -0.320x | -227.53% |
| 2014-12-31 | $-91.01 Million | $-22.82 Million | 0.251x | -4.27% |
| 2013-12-31 | $-66.08 Million | $-17.31 Million | 0.262x | -97.10% |
| 2012-12-31 | $-1.26 Million | $-11.38 Million | 9.030x | -- |
About aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinica… Read more